Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Marcos, B. (Beatriz) | - |
dc.creator | Chuang, T.T. (Tsu T.) | - |
dc.creator | Gil-Bea, F.J. (Francisco J.) | - |
dc.creator | Ramirez, M.J. (María Javier) | - |
dc.date.accessioned | 2011-12-19T09:20:48Z | - |
dc.date.available | 2011-12-19T09:20:48Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Marcos B, Chuang TT, Gil-Bea FJ, Ramirez MJ. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol 2008 Oct;155(3):434-440. | es_ES |
dc.identifier.issn | 1476-5381 | - |
dc.identifier.uri | https://hdl.handle.net/10171/20228 | - |
dc.description.abstract | BACKGROUND AND PURPOSE: The beneficial effect of 5-HT6 receptor antagonism in cognition remains controversial. This study has been undertaken to reassess the cognition enhancing properties of acute vs subchronic treatment with the selective 5-HT6 receptor antagonist SB-271046 in unimpaired rats, as well as against scopolamine (cholinergic-) or MK-801 (glutamatergic-mediated) deficits. EXPERIMENTAL APPROACH: The Morris water maze was used, measuring behaviour acquisition and retention, and swim speed. Other behavioural measures included yawning and motor activity. SB-271046 was given acutely before each trial or subchronically for 7 days before the trials. The AChE inhibitor galanthamine was also used alone or in combination with SB-271046. KEY RESULTS: Subchronic treatment with SB-271046 improved acquisition in the Morris water maze, while the acute treatment only improved retention. Neither acute nor subchronic SB-271046 treatment reversed scopolamine-induced learning deficits. MK-801 induced learning impairment associated with a behavioural syndrome, reversed by acute, but not subchronic, SB-271046 treatment. Interestingly, combined treatment with galanthamine and SB-271046 reversed the scopolamine- or MK-801-induced learning impairments. Subchronic treatment with SB-271046 did not modify motor activity or the increased number of yawns, a cholinergic-mediated behaviour, induced by single administration of SB-271046. CONCLUSIONS AND IMPLICATIONS: These data suggest a potential therapeutic role of 5-HT6 receptor antagonists such as SB-271046, alone or in combination with galanthamine, in the treatment of cognitive dysfunction, such as those seen in Alzheimer's disease and schizophrenia. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley Blackwell | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Morris water maze | es_ES |
dc.subject | Scopolamine | es_ES |
dc.subject | MK-801 | es_ES |
dc.subject | Galanthamine | es_ES |
dc.subject | Motor activity | es_ES |
dc.title | Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://onlinelibrary.wiley.com/doi/10.1038/bjp.2008.281/abstract | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
There are no files associated with this item.
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.